Follow
Celine Cano
Celine Cano
Verified email at ncl.ac.uk
Title
Cited by
Cited by
Year
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
JM Munck, MA Batey, Y Zhao, H Jenkins, CJ Richardson, C Cano, ...
Molecular cancer therapeutics 11 (8), 1789-1798, 2012
1412012
DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia
E Willmore, SL Elliott, T Mainou-Fowler, GP Summerfield, GH Jackson, ...
Clinical cancer research 14 (12), 3984-3992, 2008
1322008
Identification and Characterization of an Irreversible Inhibitor of CDK2
E Anscombe, E Meschini, R Mora-Vidal, MP Martin, D Staunton, ...
Chemistry & biology 22 (9), 1159-1164, 2015
1092015
Cyclin-dependent kinase (CDK) inhibitors: structure–activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-arylaminopurines
CR Coxon, E Anscombe, SJ Harnor, MP Martin, B Carbain, BT Golding, ...
Journal of medicinal chemistry 60 (5), 1746-1767, 2017
1002017
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure− activity relationships for DNA-dependent protein kinase inhibition …
JJ Hollick, LJM Rigoreau, C Cano-Soumillac, X Cockcroft, NJ Curtin, ...
Journal of medicinal chemistry 50 (8), 1958-1972, 2007
982007
Synthetic cannabinoid receptor agonists: classification and nomenclature
AJ Potts, C Cano, SHL Thomas, SL Hill
Clinical Toxicology 58 (2), 82-98, 2020
862020
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination
M Tavecchio, JM Munck, C Cano, DR Newell, NJ Curtin
Cancer chemotherapy and pharmacology 69, 155-164, 2012
842012
FragLites—minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation
DJ Wood, JD Lopez-Fernandez, LE Knight, I Al-Khawaldeh, C Gai, S Lin, ...
Journal of Medicinal Chemistry 62 (7), 3741-3752, 2019
772019
Targeting DNA‐dependent protein kinase for cancer therapy
SJ Harnor, A Brennan, C Cano
ChemMedChem 12 (12), 895-900, 2017
762017
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy
CE Willoughby, Y Jiang, HD Thomas, E Willmore, S Kyle, A Wittner, ...
The Journal of clinical investigation 130 (1), 258-271, 2020
592020
DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype
C Cano, OR Barbeau, C Bailey, XL Cockcroft, NJ Curtin, H Duggan, ...
Journal of medicinal chemistry 53 (24), 8498-8507, 2010
532010
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
G Beale, EJ Haagensen, HD Thomas, LZ Wang, CH Revill, SL Payne, ...
British journal of cancer 115 (6), 682-690, 2016
522016
1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity
C Cano, K Saravanan, C Bailey, J Bardos, NJ Curtin, M Frigerio, ...
Journal of medicinal chemistry 56 (16), 6386-6401, 2013
502013
Recent advances in CDK inhibitors for cancer therapy
AB Heptinstall, IWS Adiyasa, C Cano, IR Hardcastle
Future Medicinal Chemistry 10 (11), 1369-1388, 2018
472018
Trifluoroacetic Acid in 2,2,2‐Trifluoroethanol Facilitates SNAr Reactions of Heterocycles with Arylamines
B Carbain, CR Coxon, H Lebraud, KJ Elliott, CJ Matheson, E Meschini, ...
Chemistry–A European Journal 20 (8), 2311-2317, 2014
402014
Quinolinone and pyridopyrimidinone inhibitors of DNA-dependent protein kinase
OR Barbeau, C Cano-Soumillac, RJ Griffin, IR Hardcastle, GCM Smith, ...
Organic & Biomolecular Chemistry 5 (16), 2670-2677, 2007
362007
Synthesis and biological evaluation of 5-substituted O 4-alkylpyrimidines as CDK2 inhibitors
F Marchetti, C Cano, NJ Curtin, BT Golding, RJ Griffin, K Haggerty, ...
Organic & biomolecular chemistry 8 (10), 2397-2407, 2010
352010
8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK)
M Desage-El Murr, C Cano, BT Golding, IR Hardcastle, M Hummersome, ...
Bioorganic & medicinal chemistry letters 18 (17), 4885-4890, 2008
352008
Structure-based design of potent and orally active isoindolinone inhibitors of MDM2-p53 protein–protein interaction
G Chessari, IR Hardcastle, JS Ahn, B Anil, E Anscombe, RH Bawn, ...
Journal of Medicinal Chemistry 64 (7), 4071-4088, 2021
342021
Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives
KM Clapham, T Rennison, G Jones, F Craven, J Bardos, BT Golding, ...
Organic & biomolecular chemistry 10 (33), 6747-6757, 2012
332012
The system can't perform the operation now. Try again later.
Articles 1–20